Core Viewpoint - Moleculin Biotech, Inc. is set to report its financial results for the year ended December 31, 2024, on March 21, 2025, with a conference call scheduled for March 24, 2025, to discuss these results [1][2] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [1][3] - The company's lead program, Annamycin, is a next-generation anthracycline aimed at overcoming multidrug resistance and reducing cardiotoxicity associated with current treatments [3] Clinical Trials and Development - The company is initiating the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) [4] - Following a successful Phase 1B/2 study, the company believes it has de-risked the development pathway for Annamycin's potential approval for AML treatment [4] - Additionally, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and a portfolio of antimetabolites, including WP1122 for treating pathogenic viruses and certain cancer indications [5]
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast